# First-line FOLFOXIRI In Combination With Bevacizumab For Metastatic Colorectal Cancer

> **NCT01163396** · PHASE2 · COMPLETED · sponsor: **Gruppo Oncologico del Nord-Ovest** · enrollment: 57 (actual)

## Conditions studied

- Colorectal Cancer Metastatic

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Irinotecan
- **DRUG:** Oxaliplatin
- **DRUG:** 5-fluorouracil/leucovorin

## Key facts

- **NCT ID:** NCT01163396
- **Lead sponsor:** Gruppo Oncologico del Nord-Ovest
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2009-04
- **Final completion:** 2010-04
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2015-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01163396

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01163396, "First-line FOLFOXIRI In Combination With Bevacizumab For Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01163396. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*